New members

Welcome Sensorion: Pioneering New Therapies for Hearing Loss

Sensorion is a French biotech advancing innovative therapies to restore, treat and prevent hearing loss, including gene therapies for hereditary deafn

Sensorion: Pioneering New Therapies for Hearing Loss

Sensorion is a French clinical-stage biotechnology company dedicated to developing innovative therapies for inner ear disorders and hearing loss. Its approach focuses on three pillars: Restore, Treat, Prevent, with the ambition of addressing significant unmet medical needs and improving outcomes for patients.

Sensorion’s clinical pipeline includes SENS-401 (Arazasetron), which is being investigated in Phase 2 studies for cisplatin-induced ototoxicity, a form of hearing damage associated with chemotherapy, and in collaboration with Cochlear Limited for patients scheduled to undergo cochlear implantation.

The company is also advancing its gene therapy programs through a strategic collaboration with the Institut Pasteur, focused on the genetics of hearing. These programs aim to address hereditary forms of deafness, including OTOF-GT, targeting mutations in the OTOF gene, and GJB2-GT, targeting hearing loss associated with mutations in the GJB2 gene. Together, these initiatives reflect Sensorion’s commitment to developing targeted treatments for hearing loss in both adults and children.

For more information: https://www.sensorion.com/en/